Search Results

The product title you are looking for is no longer available. Other similar products that may interest you are listed below:

Refine your Search

Results for 'Ono Pharmaceutical Co Deals'
Title Publication Date Price Relevance
Ono Pharmaceutical Co., Ltd.-Deals & Alliances Report Mar 2011 £380 100%
Ono Pharmaceutical Co., Ltd. – Product Pipeline Review
H2 2011
 Nov 2011 £315 96%
Dainippon Sumitomo Pharma Co., Ltd. – Product Pipeline Review
H2 2011
 Nov 2011 £315 82%
Merck KGaA – Product Pipeline Review
H2 2011
 Nov 2011 £315 81%
Evotec Aktiengesellschaft – Product Pipeline Review
H2 2011
 Nov 2011 £315 80%
Galapagos NV – Product Pipeline Review
H2 2011
 Nov 2011 £315 80%
Progenics Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare
Deals and Alliances Profile
 Jul 2009 £160 79%
Overactive Bladder - Pipeline Review
H2 2011
 Oct 2011 £315 78%
Santen Pharmaceutical Co., Ltd. – Product Pipeline Review
H2 2011
 Nov 2011 £315 77%
Onyx Pharmaceuticals, Inc. – Product Pipeline Review
H2 2011
 Nov 2011 £315 76%
Constipation - Pipeline Review
H2 2011
 Oct 2011 £315 76%
DPP IV Inhibitors Sep 2011 £2,655 75%
Irritable Bowel Syndrome - Pipeline Review
H2 2011
 Sep 2011 £315 74%
Osteopenia - Pipeline Review
H2 2011
 Oct 2011 £315 73%
Post Menopausal Osteoporosis - Pipeline Review
H2 2011
 Aug 2011 £315 73%
Array BioPharma Inc. – Product Pipeline Review
H2 2011
 Nov 2011 £315 72%
Allergic Rhinitis - Pipeline Review
H2 2011
 Sep 2011 £315 72%
Rhinitis - Pipeline Review
H2 2011
 Sep 2011 £315 72%
Commercial Insight: Osteoporosis
Market players maximize revenue growth before the next challenging phase
 Jul 2010 £9,615 71%
Nausea and Vomiting - Pipeline Review
H2 2011
 Aug 2011 £315 71%
Thrombocytopenia - Pipeline Review
H2 2011
 Sep 2011 £315 70%
Osteoporosis - Pipeline Review
H2 2011
 Sep 2011 £315 69%
Chemotherapy Effects - Pipeline Review
H1 2012
 Jan 2012 £325 69%
Multiple Sclerosis - Pipeline Review
H2 2011
 Sep 2011 £315 69%
Motor Neurone Diseases - Pipeline Review
H2 2011
 Aug 2011 £315 69%
Kidney Cancer - Pipeline Review
H1 2012
 Jan 2012 £325 68%
Depression - Pipeline Review
Q2 2011
 Apr 2011 £315 68%
Renal Cell Carcinoma - Pipeline Review
H1 2012
 Jan 2012 £325 68%
Amyotrophic Lateral Sclerosis - Pipeline Review
H2 2011
 Sep 2011 £315 67%
Infinity Pharmaceuticals, Inc. – Product Pipeline Review
H2 2011
 Nov 2011 £315 65%